Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

bluebird bio

The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BLUE stock popped.
The post Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority Review appeared first on Investor's Business Daily.

Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority Review

Brady Corporation

Farmers & Merchants Bancorp

Ingredion

Quaker Chemical

Microsoft

Realty Income Corp

Texas Instruments

W. P. Carey

Dividend Changes: September 12-18, 2020

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel....

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

Bristol-Myers Squibb Company (BMY) Management Presents at European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Transcript)

NEW YORK--(BUSINESS WIRE)---- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis.

Bristol Myers Squibb Completes Acquisition of Forbius

Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

Dr. Reddy's Labs

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with.

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

AbbVie

CVS Health

Most stocks are anything but cheap right now. These are three great exceptions.

3 Cheap Stocks You Can Buy and Hold for Decades

NEW YORK--(BUSINESS WIRE)---- Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2020 on Thursday, November 5, 2020. During a conference call at 8:30 a.m. ET on November 5, 2020, company executives will review financial results and will address inquiries from investors and analysts.

Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

When Bristol-Myers (NYSE:BMY) acquired Celgene (CELG) in 2019, part of the package Celgene shareholders received was a tradeable contingent value right that's listed as (BMY.RT).

A Unique Security at a 68% Discount to Fair Value

Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.

Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr.

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’s

In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.45, marking a -0.13% move from the previous day.

Bristol Myers Squibb (BMY) Stock Moves -0.13%: What You Should Know

Bristol-Myers disclosed some market moving information on a Citigroup call.

The Bristol-Myers CVR Is Worth $7.83

The Bristol-Myers CVR Is Worth $6.93

CytoDyn Inc.

Gilead Sciences

Immunomedics

Inovio Pharmaceuticals

Mesoblast

Moderna

Novavax

Pfizer

Sorrento Therapeutics Inc

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

CAMBRIDGE, Mass., Sept. 15, 2020 /PRNewswire/ -- Obsidian Therapeutics, Inc.

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates BMS's Type II Variation Application for Opdivo Plus Yervoy for First-lline Treatment.

European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma

American Tower

Cerner

Colgate-Palmolive

Daily Dividend Report: AbbVie, Bristol Myers Squibb, Colgate-Palmolive, American Tower, Cerner

Archer-Daniels-Midland Company

Bank of Nova Scotia

Cardinal Health

Essex Property Trust

Federal Realty Investment Trust

General Dynamics

Intel

Merck

Omnicom Group

Oracle

Pinnacle West Capital

Prudential Financial

Reinsurance Group of America

STORE Capital

AT&T

Walgreens

When I posted my monthly update and noted my large increase in my cash position, from 4% to over 10%, some readers messaged/asked me how I intend to invest this.

I'm Investing $50,000 In These Dividend-Paying Companies

Dollar General

Vertex Pharmaceuticals

These rock-solid businesses should be resilient no matter what happens with the stock market or the economy.

3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes Again

The reliable dividend payer will probably hike its next distribution.

Bristol Myers Squibb Declares Fresh Dividend; Yield Is 3.1%

Bristol Myers Squibb (BMY) closed at $58.29 in the latest trading session, marking a -1.34% move from the prior day.

News for Bristol-Myers Stock (BMY)